Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1441 to 1450 of 2417

TitleReference numberPublishedLast updated
Nintedanib for treating idiopathic pulmonary fibrosisTA379
Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predictedTA864
Nintedanib for treating progressive fibrosing interstitial lung diseasesTA747
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA673
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancerTA784
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19TA878
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)TA980
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic diseaseTA684
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancerTA746

Results per page

  1. 10
  2. 25
  3. 50
  4. All